Certest Biotec, established in Zaragoza in 2002, is an innovative and technology-based company that has always based its growth on research and development of new products, as well as exploring new market niches and opportunities.

It is comprised of four divisions, which include: Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology under the brand VIASURE by Certest, and Pharma. The latter, created in 2021, specializes in advanced lipid nanoparticle technology, focusing on the development of effective and specific LNPs for next-generation drugs. Their technology includes patented high-performance ionizable lipids and optimized LNP formulations with excellent in vivo performance.

Additionally, the expertise of their highly qualified staff, currently with more than 300 employees, is available to their clients, offering development and manufacturing services for the production of their own materials.

The excellence of their products is supported by antigens, antibodies, and molecular enzymes manufactured by their Raw Materials division, also available to third parties. The key to understanding Certest's success is its business purpose: "Improving global health by providing an immediate response through our human potential."

  • More than 25,000m2 of facilities.
  • Presence in more than 130 countries.
  • €17M invested in R&D since 2019.



Polígono Industrial Río Gállego II, calle J nº 1.

E-50840 San Mateo de Gállego, Zaragoza, Spain

Website: www.certest.es

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +34 976 520 354

Fax: +34 976 106 268

Certest new 001


Certest new 003